Related Experiment Video
Updated: Jul 29, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach
Elaine Wong1, Timothy V Nguyen1
1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York.
Abstract:
Sodium glucose co-transporter-2 (SGLT2) inhibitors have been of substantial interest to clinicians, initially in connection to diabetes management. Beyond its expected antihyperglycemic effects, this drug class is associated with properties such as promoting diuresis, improving cardiac remodeling, and decreasing albuminuria. Considering these beneficial outcomes, the potential roles for SGLT2 inhibitors have evolved to include other therapeutic areas. This review uses a case-based approach to showcase the expanded indications of SGLT2 inhibitors in the setting of heart failure and chronic kidney disease for patients without diabetes.
Related Concept Videos
Secondary Active Transport
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas

